HOPO Therapeutics Awarded $226 Million Contract from BARDA for Advanced Development of Oral Decorporation Agent
HOPO Therapeutics Awarded $226 Million Contract from BARDA for Advanced Development of Oral Decorporation Agent
10/28/24, 2:19 PM
Location
berkeleyMoney
$226 million
Industry
biotechnology
manufacturing
Type
contract
HOPO Therapeutics, Inc. has been awarded a contract valued at up to $226 million from the Biomedical Advanced Research and Development Authority (BARDA) to advance the development of the drug candidate HOPO-101 as a medical countermeasure against radiological threats. The funds will be used for toxicology and pharmacology studies, manufacturing activities, and nonclinical research in heavy metal poisoning, with additional funding available for later-stage development upon agreement between BARDA and HOPO.
Company Info
Location
berkeley, california, united states
Additional Info
HOPO Therapeutics, Inc. is a company focused on developing decorporation agents for heavy metal toxicity, with a mission to provide rapid access to treatment for an exposed population during radiological or nuclear disasters.